At a glance
ClinicalIndex Comparison RecordPhase 1Recruiting· 18 target
Drug / intervention
19-28z/IL-18 CAR T cellsbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I Trial of CD19-targeted Chimeric Antigen Receptor (CAR) T Cells That Constitutively Secrete Interleukin 18 (19-28z/IL-18) in Patients With Relapsed or Refractory (R/R) Acute Lymphoblastic Leukemia (ALL)
In Brief
A Phase 1 clinical trial evaluating 19-28z/IL-18 CAR T cells for Philadelphia-Negative ALL and 5 related conditions. Currently recruiting, targeting 18 participants across 7 sites.
Signals
Enrolling ahead of pace
Detailed Summary
Participants will have a sample of their white blood cells, called T cells, collected using a procedure called leukapheresis. The collected T cells will be sent to a laboratory to be changed (modified) to become 19-28z/IL-18, the CAR T-cell therapy that participants will receive during the study. Making the participants' study therapy will take about 2-4 weeks.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPhiladelphia-Negative ALL, Philadelphia-Positive ALL, Relapsed ALL, Adult, Refractory Acute Lymphoblastic Leukemia, Refractory Acute Lymphoblastic Leukemia (ALL), Refractory Acute Lymphoid Leukemia in Relapse
CountriesUnited States
Collaborators--
Timeline
Phase 1Recruiting
2025202620272028
Enrollment StartFeb 2024
First PostedMar 2024
TodayJul 2026
Primary CompletionFeb 2028
First PostedMar 1, 2024
Enrollment StartFeb 23, 2024
Primary CompletionFeb 23, 2028
TodayJul 1, 2026
Enrollment to primary: 4 yearsPosted 2.3 years agoPrimary completion in 1.6 years
Interventions
19-28z/IL-18 CAR T cellsbiological
19-28z/IL-18 CAR T cells are an investigational new drug (IND) for the treatment of R/R B-ALL